IGC PHARMA, INC. Research and Development Expense
IGC PHARMA, INC. (IGC) reported Research and Development Expense of $1.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-14
- IGC PHARMA, INC. research and development expense for the quarter ending 2026-06-30 was $1.39M, a 63.34% increase year-over-year.
- IGC PHARMA, INC. research and development expense for the quarter ending 2026-03-31 was $1.27M, a 27.58% increase year-over-year.
- IGC PHARMA, INC. research and development expense for the quarter ending 2025-12-31 was $1.48M, a 73.94% increase year-over-year.
- IGC PHARMA, INC. research and development expense for the quarter ending 2025-09-30 was $1.59M, a 73.17% increase year-over-year.
- IGC PHARMA, INC. research and development expense for fiscal 2025 was $3.65M, a 3.13% decline from fiscal 2024.
- IGC PHARMA, INC. research and development expense for fiscal 2024 was $3.77M, a 9.01% increase from fiscal 2023.
- IGC PHARMA, INC. research and development expense for fiscal 2023 was $3.46M, a 48.54% increase from fiscal 2022.
- IGC PHARMA, INC. research and development expense for fiscal 2022 was $2.33M, a 150.81% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $1.39M 10-Q · filed 2026-08-14 | $2.66M 10-Q · filed 2026-08-14 | $4.14M derived: sum of 3 quarters · filed 2026-08-14 | $5.73M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2026-03-31 | $1.27M 10-Q · filed 2026-05-15 | $2.75M derived: sum of 2 quarters · filed 2026-05-15 | $4.34M derived: sum of 3 quarters · filed 2026-05-15 | $5.19M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-12-31 | $1.48M derived: 10-KT 9 month − 10-Q 6 month · filed 2026-03-18 | $3.07M derived: sum of 2 quarters · filed 2026-03-18 | $3.92M 10-KT · filed 2026-03-18 | $4.92M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-09-30 | $1.59M 10-Q · filed 2025-11-14 | $2.44M 10-Q · filed 2025-11-14 | $3.44M derived: sum of 3 quarters · filed 2026-08-14 | $4.29M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-06-30 | $851.00K 10-Q · filed 2026-08-14 | $1.85M 10-Q · filed 2026-08-14 | $2.70M derived: sum of 3 quarters · filed 2026-08-14 | $3.62M derived: sum of 4 quarters · filed 2026-08-14 | |
| 2025-03-31 | $997.00K 10-Q · filed 2026-05-15 | $1.85M derived: sum of 2 quarters · filed 2026-05-15 | $2.77M derived: sum of 3 quarters · filed 2026-05-15 | $3.65M 10-KT · filed 2026-03-18 | |
| 2024-12-31 | $852.00K 10-Q · filed 2025-02-14 | $1.77M derived: sum of 2 quarters · filed 2025-11-14 | $2.66M 10-KT · filed 2026-03-18 | $3.51M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-09-30 | $917.00K 10-Q · filed 2025-11-14 | $1.81M 10-Q · filed 2025-11-14 | $2.66M derived: sum of 3 quarters · filed 2025-11-14 | $3.56M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | $889.00K 10-Q · filed 2025-08-14 | $1.74M derived: sum of 2 quarters · filed 2025-08-14 | $2.65M derived: sum of 3 quarters · filed 2025-08-14 | $3.92M derived: sum of 4 quarters · filed 2025-08-14 | |
| 2024-03-31 | $855.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-06-27 | $1.76M derived: sum of 2 quarters · filed 2025-06-27 | $3.03M derived: sum of 3 quarters · filed 2025-06-27 | $3.77M 10-K · filed 2025-06-27 | |
| 2023-12-31 | $903.00K 10-Q · filed 2025-02-14 | $2.17M derived: sum of 2 quarters · filed 2025-02-14 | $2.92M 10-Q · filed 2025-02-14 | $3.41M derived: sum of 4 quarters · filed 2025-02-14 | |
| 2023-09-30 | $1.27M 10-Q · filed 2024-11-12 | $2.02M 10-Q · filed 2024-11-12 | $2.51M derived: sum of 3 quarters · filed 2024-11-12 | $3.31M derived: sum of 4 quarters · filed 2024-11-12 | |
| 2023-06-30 | $747.00K 10-Q · filed 2024-08-07 | $1.24M derived: sum of 2 quarters · filed 2024-08-07 | $2.05M derived: sum of 3 quarters · filed 2024-08-07 | $2.81M derived: sum of 4 quarters · filed 2024-08-07 | |
| 2023-03-31 | $493.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-24 | $1.30M derived: sum of 2 quarters · filed 2024-06-24 | $2.07M derived: sum of 3 quarters · filed 2024-06-24 | $3.46M 10-K · filed 2024-06-24 | |
| 2022-12-31 | $806.00K 10-Q · filed 2024-02-14 | $1.57M derived: sum of 2 quarters · filed 2024-02-14 | $2.97M 10-Q · filed 2024-02-14 | $4.20M derived: sum of 4 quarters · filed 2024-02-14 | |
| 2022-09-30 | $768.00K 10-Q · filed 2023-11-09 | $2.16M 10-Q · filed 2023-11-09 | $3.40M derived: sum of 3 quarters · filed 2023-11-09 | $3.77M derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.39M 10-Q · filed 2023-08-10 | $2.63M derived: sum of 2 quarters · filed 2023-08-10 | $3.00M derived: sum of 3 quarters · filed 2023-08-10 | $3.28M derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2023-07-07 | $1.61M derived: sum of 2 quarters · filed 2023-07-07 | $1.89M derived: sum of 3 quarters · filed 2023-07-07 | $2.33M 10-K · filed 2023-07-07 | |
| 2021-12-31 | $377.00K 10-Q · filed 2023-02-14 | $653.00K derived: sum of 2 quarters · filed 2023-02-14 | $1.10M 10-Q · filed 2023-02-14 | $1.43M derived: sum of 4 quarters · filed 2023-02-14 | |
| 2021-09-30 | $276.00K 10-Q · filed 2022-11-01 | $720.00K 10-Q · filed 2022-11-01 | $1.05M derived: sum of 3 quarters · filed 2022-11-01 | $1.21M derived: sum of 4 quarters · filed 2022-11-01 | |
| 2021-06-30 | $444.00K 10-Q · filed 2022-08-05 | $778.00K derived: sum of 2 quarters · filed 2022-08-05 | $932.00K derived: sum of 3 quarters · filed 2022-08-05 | $1.15M derived: sum of 4 quarters · filed 2022-08-05 | |
| 2021-03-31 | $334.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-06-23 | $488.00K derived: sum of 2 quarters · filed 2022-06-23 | $707.00K derived: sum of 3 quarters · filed 2022-06-23 | $929.00K 10-K · filed 2022-06-23 | |
| 2020-12-31 | $154.00K 10-Q · filed 2022-02-10 | $373.00K derived: sum of 2 quarters · filed 2022-02-10 | $595.00K 10-Q · filed 2022-02-10 | $842.00K derived: sum of 4 quarters · filed 2022-02-10 | |
| 2020-09-30 | $219.00K 10-Q · filed 2021-10-29 | $441.00K 10-Q · filed 2021-10-29 | $688.00K derived: sum of 3 quarters · filed 2021-10-29 | $983.00K derived: sum of 4 quarters · filed 2021-10-29 | |
| 2020-06-30 | $222.00K 10-Q · filed 2021-08-11 | $469.00K derived: sum of 2 quarters · filed 2021-08-11 | $764.00K derived: sum of 3 quarters · filed 2021-08-11 | $986.00K derived: sum of 4 quarters · filed 2021-08-11 | |
| 2020-03-31 | $247.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-06-14 | $542.00K derived: sum of 2 quarters · filed 2021-06-14 | $764.00K derived: sum of 3 quarters · filed 2021-06-14 | $1.01M 10-K · filed 2021-06-14 | |
| 2019-12-31 | $295.00K 10-Q · filed 2021-02-16 | $517.00K derived: sum of 2 quarters · filed 2021-02-16 | $764.00K 10-Q · filed 2021-02-16 | $1.57M derived: sum of 4 quarters · filed 2021-02-16 | |
| 2019-09-30 | $222.00K 10-Q · filed 2020-11-20 | $469.00K 10-Q · filed 2020-11-20 | $1.28M derived: sum of 3 quarters · filed 2020-11-20 | $1.45M derived: sum of 4 quarters · filed 2020-11-20 | |
| 2019-06-30 | $247.00K 10-Q · filed 2020-08-19 | $1.06M derived: sum of 2 quarters · filed 2020-08-19 | $1.22M derived: sum of 3 quarters · filed 2020-08-19 | $1.50M derived: sum of 4 quarters · filed 2020-08-19 | |
| 2019-03-31 | $811.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-07-13 | $977.00K derived: sum of 2 quarters · filed 2020-07-13 | $1.25M derived: sum of 3 quarters · filed 2020-07-13 | $1.26M 10-K · filed 2020-07-13 | |
| 2018-12-31 | $166.00K 10-Q · filed 2020-02-10 | $444.00K derived: sum of 2 quarters · filed 2020-02-10 | $445.00K 10-Q · filed 2020-02-10 | $559.00K derived: sum of 4 quarters · filed 2020-02-10 | |
| 2018-09-30 | $278.00K 10-Q · filed 2019-11-06 | $237.00K 10-Q · filed 2018-10-16 | $278.00K 10-Q · filed 2019-11-06 | $393.00K derived: sum of 3 quarters · filed 2019-11-06 | $393.00K derived: sum of 4 quarters · filed 2019-11-06 |
| 2018-06-30 | $36.00K 10-Q · filed 2019-08-09 | $37.38K 10-Q · filed 2018-08-03 | $115.00K derived: sum of 2 quarters · filed 2019-08-09 | $115.00K derived: sum of 3 quarters · filed 2019-08-09 | $193.00K derived: sum of 4 quarters · filed 2019-08-09 |
| 2018-03-31 | $79.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-06-14 | $79.00K derived: sum of 2 quarters · filed 2019-06-14 | $157.00K derived: sum of 3 quarters · filed 2019-06-14 | $137.00K 10-K · filed 2019-06-14 | |
| 2017-12-31 | $0.00 10-Q · filed 2019-02-12 | $78.00K derived: sum of 2 quarters · filed 2019-02-12 | $58.00K 10-Q · filed 2019-02-12 | ||
| 2017-09-30 | $78.00K 10-Q · filed 2018-10-16 | $134.54K derived: sum of 2 quarters · filed 2018-10-16 | |||
| 2017-06-30 | $56.54K 10-Q · filed 2018-08-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |